Annovis Bio (ANVS) Preferred Stock Liabilities (2019)
Annovis Bio (ANVS) posted Preferred Stock Liabilities of $567649.0 for Q4 2019, little changed sequentially from $567649.0 in Q3 2019.
Annovis Bio (ANVS) Preferred Stock Liabilities (2019) Analysis & Trends
Annovis Bio has reported Preferred Stock Liabilities for 1 years, with the latest figure at $567649.0 in Q4 2019.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $567649.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $567649.0 (changed N/A YoY) and the FY2019 annual result came in at $567649.0, changed N/A from the prior year.
- Preferred Stock Liabilities held at $567649.0 in Q4 2019 per ANVS's latest filing, from $567649.0 in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $6.5 million in Q1 2019 and troughed at $567649.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 567,649.00 |
| Sep 30, 2019 | 567,649.00 |
| Jun 30, 2019 | 6.51 Mn |
| Mar 31, 2019 | 6.51 Mn |